Elevated prostate specific antigen and reduced 10-year survival among a cohort of Danish men consecutively referred from primary care to an urological department during 2005–2006

References

• Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology 1993;42:276–82.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 1992;70:291–301.
   PubMed Web of Science ®Google Scholar
• Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TL, Smith DS, Catalona WJ. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 1992;147:810–4.
   PubMed Web of Science ®Google Scholar
• Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907–23.
   PubMed Web of Science ®Google Scholar
• Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143:747–52.
   PubMed Web of Science ®Google Scholar
• Bahnson RR. Elevation of prostate specific antigen from bacillus Calmette-Guerin-induced granulomatous prostatitis. J Urol 1991;146:1368–9.
   PubMed Web of Science ®Google Scholar
• Christensson A, Björk T, Nilsson O, Dahlen U, Matikainen MT, Cockett AT, Abrahamsson PA, Lilja H. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100–5.
   PubMed Web of Science ®Google Scholar
• Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222–6.
   PubMed Web of Science ®Google Scholar
• Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594–8.
   PubMed Web of Science ®Google Scholar
• Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995;46:187–94.
   PubMed Web of Science ®Google Scholar
• Abrahamsson PA, Lilja H, Oesterling JE. Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol Clin North Am 1997;24:353–65.
   PubMed Web of Science ®Google Scholar
• Loeb S, Carter HB, Catalona WJ, Moul JW, Schroder FH. Baseline prostate-specific antigen testing at a young age. Eur Urol 2012;61:1–7.
   PubMed Web of Science ®Google Scholar
• Bjartell A, Montironi R, Berney DM, Egevad L. Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol 2011;50:76–84.
   PubMed Web of Science ®Google Scholar
• Ilic D, O’Connor D, Green S, Wilt TJ. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 2011;107:882–91.
   PubMed Web of Science ®Google Scholar
• van Leeuwen PJ, Kölble K, Huland H, Hambrock T, Barentsz J, Schröder FH. Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies. Eur Urol 2011;59:183–90.
   PubMed Web of Science ®Google Scholar
• Hegarty J, Beirne PV, Walsh E, Comber H, Fitzgerald T, Wallace Kazer M. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database Syst Rev 2010;11:CD006590.
   PubMed Web of Science ®Google Scholar
• Schröder FH, Denis L, Roobol MJ. Epilogue: different approaches for prostate cancer screening in the EU? Eur J Cancer 2010;46:3120–5.
   PubMed Web of Science ®Google Scholar
• Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, Babaian R, Childs SJ, Stamey T, Fritsche HA, Sokoll L, Chan DW, Thiel RP, Cheli CD. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003;170:1787–91.
   PubMed Web of Science ®Google Scholar
• Jung K, Elgeti U, Lein M, Brux B, Sinha P, Rudolph B, Hauptmann S, Schnorr D, Loening SA. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?. Clin Chem 2000;46:55–62.
   PubMed Web of Science ®Google Scholar
• Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011;39:22–5.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. STROBE Initiative, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ 2007;85:867–72.
   PubMed Web of Science ®Google Scholar
• Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860–4.
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Cronin AM, Roobol MJ, Hugosson J, Jones JS, Kattan MW, Klein E, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Schröder FH, Lilja H. The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res 2010;16:4374–81.
   PubMed Web of Science ®Google Scholar
• Larsen SB, Brasso K, Iversen P, Christensen PJ, Christiansen M, Carlsson S, Lilja H, Friis S, Tjonneland A, Dalton SO. Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort. Eur J Cancer 2013;49:3041–8.
   PubMed Web of Science ®Google Scholar
• Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, Schennach H, Schafer G, Frauscher F, Boniol M, Severi G, Robertson C, Boyle P. Tyrol Prostate Cancer Screening Group, Tyrol prostate cancer demonstration project: early detection, treatment, outcome, incidence and mortality. BJU Int 2008;101:809–16.
   PubMed Web of Science ®Google Scholar
• Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, Stattin P. Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories. Scand J Urol 2014;48:426–35.
   PubMed Web of Science ®Google Scholar
• Strittmatter F, Stieber P, Nagel D, Fullhase C, Walther S, Stief CG, Waidelich R. Detection of prostate cancer with complexed PSA and complexed/total PSA ratio: is there any advantage? Eur J Med Res 2011;16:445–50.
   PubMed Web of Science ®Google Scholar